company_id,asset_id,asset_name,aliases,stage,therapeutic_area,as_of_date,indication
immatics,22,IMA203CD8,IMA203CD8,Phase 1,Oncology,,Gynecologic cancers; other solid cancers
immatics,25,IMA401,IMA401,Phase 1,Oncology,,"HNSCC, sqNSCLC, other solid cancers"
immatics,23,IMA402,IMA402,Phase 1,Oncology,,"Melanoma, gynecologic cancers, other solid cancers"
immatics,24,IMA402 + ICI,ICI; IMA402; IMA402 + ICI,Phase 1,Oncology,,"Melanoma, gynecologic cancers, other solid cancers (combo)"
immatics,26,Undisclosed bispecific,Undisclosed bispecific,Preclinical,Oncology,,Undisclosed
immatics,27,Undisclosed cell therapy,Undisclosed cell therapy,Preclinical,Oncology,,Undisclosed
